MX9806209A - Proceso para la preparacion de d-treo-(r,r)-metil fenidato y recirculacion de enantiomeros no deseados a traves de epimerizacion. - Google Patents
Proceso para la preparacion de d-treo-(r,r)-metil fenidato y recirculacion de enantiomeros no deseados a traves de epimerizacion.Info
- Publication number
- MX9806209A MX9806209A MX9806209A MX9806209A MX9806209A MX 9806209 A MX9806209 A MX 9806209A MX 9806209 A MX9806209 A MX 9806209A MX 9806209 A MX9806209 A MX 9806209A MX 9806209 A MX9806209 A MX 9806209A
- Authority
- MX
- Mexico
- Prior art keywords
- threo
- epimerisation
- recycling
- preparation
- enantiomers
- Prior art date
Links
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 229960001344 methylphenidate Drugs 0.000 title 1
- 238000004064 recycling Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical class O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 abstract 1
- DUGOZIWVEXMGBE-OLZOCXBDSA-N methyl (S)-phenyl[(R)-piperidin-2-yl]acetate Chemical compound C([C@@H]1[C@@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 DUGOZIWVEXMGBE-OLZOCXBDSA-N 0.000 abstract 1
- 238000000926 separation method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D9/00—Crystallisation
- B01D9/0004—Crystallisation cooling by heat exchange
- B01D9/0013—Crystallisation cooling by heat exchange by indirect heat exchange
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Thermal Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Un proceso para mantener un enantiomero individual, d o 1, de treo-metilfenidato, comprende la resolucion de la mezcla de los enantiomeros; la racemizacion del enantiomero no deseado para dar una mezcla de los cuatro esteroisomeros; y la separacion de los esteroisomeros eritro para dejar la mezcla para resolucion.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9602174.6A GB9602174D0 (en) | 1996-02-02 | 1996-02-02 | Resolution/racemization process |
GBGB9618836.2A GB9618836D0 (en) | 1996-09-10 | 1996-09-10 | Resolution/racemisation process |
Publications (2)
Publication Number | Publication Date |
---|---|
MX9806209A true MX9806209A (es) | 1998-10-31 |
MX209701B MX209701B (es) | 2002-08-15 |
Family
ID=26308593
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9806209A MX209701B (es) | 1996-02-02 | 1998-07-31 | Proceso para la preparacion de d-treo-(r,r)-metil fenidato y recirculacion de enantiomeros no deseados a traves de epimerizacion. |
Country Status (16)
Country | Link |
---|---|
US (1) | US7164025B2 (es) |
EP (1) | EP0879228B1 (es) |
JP (1) | JP2000504008A (es) |
KR (1) | KR100453707B1 (es) |
AT (1) | ATE226940T1 (es) |
AU (1) | AU715183B2 (es) |
CA (1) | CA2243534C (es) |
CZ (1) | CZ292609B6 (es) |
DE (1) | DE69716713T2 (es) |
DK (1) | DK0879228T3 (es) |
ES (1) | ES2187753T3 (es) |
HU (1) | HUP9901658A3 (es) |
MX (1) | MX209701B (es) |
PT (1) | PT879228E (es) |
SK (1) | SK283553B6 (es) |
WO (1) | WO1997028124A1 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6486177B2 (en) * | 1995-12-04 | 2002-11-26 | Celgene Corporation | Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate |
US5922736A (en) * | 1995-12-04 | 1999-07-13 | Celegene Corporation | Chronic, bolus administration of D-threo methylphenidate |
US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
GB9700912D0 (en) * | 1997-01-17 | 1997-03-05 | Chiroscience Ltd | Resolution |
US6962997B1 (en) | 1997-05-22 | 2005-11-08 | Celgene Corporation | Process and intermediates for resolving piperidyl acetamide steroisomers |
US6100401A (en) * | 1998-04-20 | 2000-08-08 | Novartris Ag | Process for preparing the d-threo isomer of methylphenidate hydrochloride |
US6025502A (en) * | 1999-03-19 | 2000-02-15 | The Trustees Of The University Of Pennsylvania | Enantopselective synthesis of methyl phenidate |
US20050239830A1 (en) * | 2004-04-26 | 2005-10-27 | Vikram Khetani | Methods of diminishing co-abuse potential |
AU2005313887B2 (en) * | 2004-12-09 | 2011-10-27 | Celgene Corporation | Treatment using D-threo methylphenidate |
US7897777B2 (en) * | 2007-01-05 | 2011-03-01 | Archimica, Inc. | Process of enantiomeric resolution of D,L-(±)-threo-methylphenidate |
WO2012031125A2 (en) | 2010-09-01 | 2012-03-08 | The General Hospital Corporation | Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine |
US9603809B2 (en) | 2011-03-23 | 2017-03-28 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
US10905652B2 (en) | 2011-03-23 | 2021-02-02 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
DK4011364T3 (da) | 2011-03-23 | 2024-03-18 | Ironshore Pharmaceuticals & Dev Inc | Fremgangsmåder og sammensætninger til behandling af ADD (Attention Deficit Disorder) |
US9498447B2 (en) | 2011-03-23 | 2016-11-22 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US9119809B2 (en) | 2011-03-23 | 2015-09-01 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US8916588B2 (en) | 2011-03-23 | 2014-12-23 | Ironshore Pharmaceuticals & Development, Inc. | Methods for treatment of attention deficit hyperactivity disorder |
US10292937B2 (en) | 2011-03-23 | 2019-05-21 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
US9283214B2 (en) | 2011-03-23 | 2016-03-15 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US8927010B2 (en) | 2011-03-23 | 2015-01-06 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US11241391B2 (en) | 2011-03-23 | 2022-02-08 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2957880A (en) * | 1953-12-23 | 1960-10-25 | Ciba Pharm Prod Inc | Process for the conversion of stereoisomers |
SU466229A1 (ru) * | 1973-01-23 | 1975-04-05 | Всесоюзный научно-исследовательский химико-фармацевтический институт им. С.Орджоникидзе | Способ получени гидрохлорида метилового эфира трео- -фенил- (пиперидил-2)-уксусной кислоты |
US4254261A (en) * | 1979-10-15 | 1981-03-03 | Merck & Co., Inc. | Dehydroabietylammonium salts of 6-oxo-2-piperidinecarboxylic acid |
US5733756A (en) * | 1996-01-05 | 1998-03-31 | Celgene Corporation | Lactams and processes for stereoselective enrichment of lactams, amides, and esters |
MX9805870A (es) * | 1996-01-22 | 1999-01-31 | ||
US6242464B1 (en) * | 1996-01-22 | 2001-06-05 | Chiroscience Limited | Single isomer methylphenidate and resolution process |
GB9604943D0 (en) * | 1996-03-08 | 1996-05-08 | Chiroscience Ltd | Resolution |
-
1997
- 1997-01-31 KR KR19980705911A patent/KR100453707B1/ko not_active IP Right Cessation
- 1997-01-31 DE DE69716713T patent/DE69716713T2/de not_active Expired - Fee Related
- 1997-01-31 AU AU16082/97A patent/AU715183B2/en not_active Ceased
- 1997-01-31 SK SK979-98A patent/SK283553B6/sk unknown
- 1997-01-31 EP EP97902435A patent/EP0879228B1/en not_active Expired - Lifetime
- 1997-01-31 ES ES97902435T patent/ES2187753T3/es not_active Expired - Lifetime
- 1997-01-31 JP JP9527425A patent/JP2000504008A/ja not_active Ceased
- 1997-01-31 DK DK97902435T patent/DK0879228T3/da active
- 1997-01-31 HU HU9901658A patent/HUP9901658A3/hu unknown
- 1997-01-31 CZ CZ19982275A patent/CZ292609B6/cs not_active IP Right Cessation
- 1997-01-31 WO PCT/GB1997/000281 patent/WO1997028124A1/en active IP Right Grant
- 1997-01-31 PT PT97902435T patent/PT879228E/pt unknown
- 1997-01-31 AT AT97902435T patent/ATE226940T1/de not_active IP Right Cessation
- 1997-01-31 CA CA002243534A patent/CA2243534C/en not_active Expired - Fee Related
-
1998
- 1998-07-31 MX MX9806209A patent/MX209701B/es not_active IP Right Cessation
-
2001
- 2001-08-10 US US09/928,139 patent/US7164025B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ATE226940T1 (de) | 2002-11-15 |
KR19990082186A (ko) | 1999-11-25 |
US7164025B2 (en) | 2007-01-16 |
HUP9901658A2 (hu) | 1999-09-28 |
DK0879228T3 (da) | 2003-03-03 |
SK283553B6 (sk) | 2003-09-11 |
MX209701B (es) | 2002-08-15 |
EP0879228A1 (en) | 1998-11-25 |
AU1608297A (en) | 1997-08-22 |
KR100453707B1 (ko) | 2005-01-25 |
DE69716713D1 (de) | 2002-12-05 |
US20020032335A1 (en) | 2002-03-14 |
AU715183B2 (en) | 2000-01-20 |
EP0879228B1 (en) | 2002-10-30 |
CA2243534A1 (en) | 1997-08-07 |
CA2243534C (en) | 2003-08-26 |
PT879228E (pt) | 2003-01-31 |
SK97998A3 (en) | 1999-01-11 |
WO1997028124A1 (en) | 1997-08-07 |
CZ292609B6 (cs) | 2003-11-12 |
CZ227598A3 (cs) | 1998-12-16 |
JP2000504008A (ja) | 2000-04-04 |
DE69716713T2 (de) | 2003-07-03 |
HUP9901658A3 (en) | 1999-12-28 |
ES2187753T3 (es) | 2003-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9806209A (es) | Proceso para la preparacion de d-treo-(r,r)-metil fenidato y recirculacion de enantiomeros no deseados a traves de epimerizacion. | |
IE891859L (en) | New enantiomers and their isolation | |
MY121543A (en) | Preparation of 3,4,4-trisubstituted-piperidinyl-n- alkylcarboxylates and intermediates | |
AU1789797A (en) | Process for producing L-glutamic acid by fermentation | |
HUP9701652A3 (en) | Process for producing l-amino acid through fermentation | |
EP0670370A3 (en) | Process for the preparation of glutamic acid by fermentation. | |
HU9601857D0 (en) | New benzyl-piperidine- or -tetrahydro-pyridine derivatives and processes for producing them | |
MY116593A (en) | Process for the preparation of o-demethyltramadol enantiomers | |
AU2102497A (en) | Resolution of threo-methylphenidate | |
HUP9900149A3 (en) | Process for producing l-lysine by fermentation | |
BG102788A (en) | New methods for the preparation of intermediate compounds for presticides | |
EP1004671A4 (en) | METHOD FOR THE PRODUCTION OF L-GLUTAMIC ACID BY FERMENTATION | |
MX9708013A (es) | Procedimiento para preparar 1-(piridil)-2-ciclohexil-amina racemica y enantiomera. | |
AU6578400A (en) | Novel method for preparing benzoperhydroisoindole compounds | |
HUP9801083A3 (en) | Process for producing (15,4r)- or (1r,4s)-4-[(2-amino-6-chloro-9h-purin)-9-yl]-2-cyclopentene-1-methanol | |
AU1319697A (en) | Process for producing oleanolic acid analogs by culturing hairy root | |
UA48993C2 (uk) | СПОСІБ ОТРИМАННЯ N-АЦЕТИЛ-(L)-4-ЦІАНОФЕНІЛАЛАНІНУ Аc-(L)-Phe(4-CN)-OH І N-АЦЕТИЛ-(L)-П-АМІДИНФЕНІЛАЛАНІН-ЦИКЛОГЕКСИЛГЛІЦИН-<font face="Symbol">b</font>-(3-N-МЕТИЛПІРИДИН)-АЛАНІНУ Аc-(L)-pАph-Сhg-PalMe(3)-NH<sub>2</sub> | |
ZA954518B (en) | Method of producing l-lysine by fermentation | |
HU9500233D0 (en) | Improved process for producing pharmaceutical intermediates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
MM | Annulment or lapse due to non-payment of fees |